NZ792553B2 - Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells - Google Patents
Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells Download PDFInfo
- Publication number
- NZ792553B2 NZ792553B2 NZ792553A NZ79255312A NZ792553B2 NZ 792553 B2 NZ792553 B2 NZ 792553B2 NZ 792553 A NZ792553 A NZ 792553A NZ 79255312 A NZ79255312 A NZ 79255312A NZ 792553 B2 NZ792553 B2 NZ 792553B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pbmcs
- composition
- medicinal composition
- ivf
- hcg
- Prior art date
Links
Abstract
Disclosed is a method of in vitro fertilization in which the embryo is implanted into the uterus of a female patient at least two months after the eggs are retrieved from the patient, in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy. Wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
Claims (28)
1. A method of producing a medicinal composition comprising cultured peripheral blood mononuclear cells (PBMCs) for the treatment of endometrial a tissue, the method comprising the steps of: (a) providing a portion of PBMCs obtained from the blood of a patient at least two months after an -system-influencing event or an endocrine-system-influencing event that comprises controlled ovary stimulation or oocyte retrieval during a cycle of in vitro fertilization (IVF) treatment, and (b) propagating said portion of PBMCs from (a) in a culture medium containing human chorionic gonadotropin (HCG) or an HCG equivalent in the presence of 0% carbon dioxide (CO2) to obtain the medicinal composition wherein an amount of the HCG or HCG equivalent is sufficient to permit the PBMCs in the medicinal composition to enhance growth of trial tissue in a patient receiving the medicinal composition compared to a patient receiving a l composition wherein the PBMCs were not provided according to step (a).
2. The method of claim 1, further comprising formulating a composition comprising a nonpropagated portion of the PBMCs of (a) with the ated portion of PBMCs from step (b).
3. The method of claim 1 or claim 2, further comprising combining a fresh portion of PBMCs from a patient with the propagated PBMCs from (b).
4. The method of claim 3, wherein the fresh portion of PBMCs is obtained from a different patient than the PBMCs of (a).
5. The method of claim 3 or 4, further comprising the step of repeating step (a) and step (b) to obtain a desired amount of cultured PBMCs.
6. The method of any one of claims 1 to 5, wherein the culture medium is RPMI 1640 .
7. The method of any one of claims 1 to 6, wherein the culture medium comprises L-glutamine and sodium bicarbonate.
8.The method of any one of claims 1 to 7, wherein the culture medium comprises a protein for feeding the PBMCs that are cultured in the medium.
9. The method of claim 8, wherein the protein ses human recombinant albumin or a promoting agent capable of ing the y of PBMCs to enhance tissue growth.
10. The method of any one of claims 1 to 9, wherein the promoting agent is human chorionic gonadotropin (HCG) having a minimal concentration of 5 IU/mL in the PBMC culture medium
11. The method of any one of claims 1 to 10, wherein the culture medium comprises: (i) RPMI 1640 medium with L-glutamine and sodium bicarbonate, (ii) human recombinant albumin, and (iii) the promoting agent which is human nic gonadotropin (HCG) or an HCG equivalent capable of improving the ability of PBMCs to enhance tissue growth.
12. The method of any one of claims 1 to 11, wherein the step of propagating said portions of PBMCs in the presence of 4.8-6.0% carbon dioxide (CO2) in a culture medium is med at a ature of 36.7-37.3°C.
13. The method of any one of claims 1 to 12, wherein the step of propagating said portions of PBMCs in the presence of 4.8-6.0% carbon dioxide (CO2) in a e medium is performed for a period of time in the range of 46 to 72 hours.
14. The method of any one of claims 1 to 13, wherein the PBMCs are cultured in vitro on fibronectin.
15. The method of any one of claims 1 to 14, wherein the immune-system-influencing event or the endocrine-system-influencing event comprises controlled ovary stimulation or oocyte retrieval during IVF treatment.
16. The method of any one of claims 1 to 15, wherein the concentration of total PBMCs in the ed composition is in the range of 4 to 8 million cells per millilitre of said composition.
17. A medicinal composition comprising PBMCs obtained by the method as defined in any one of claims 1 to 16, wherein the medicinal composition is formulated for use in decreasing autoimmune reactions during an in vitro fertilization (IVF) treatment.
18. A medicinal composition sing PBMCs obtained by the method as defined in any one of claims 1 to 16, wherein the nal composition is formulated for use in repairing, engineering, restoring, building, regenerating, or treating a tissue by growing the tissue in the ce of the composition of PBMCs, wherein the tissue is the endometrium of the uterus.
19. The medicinal composition of claim 18, n the PBMCs are used as building blocks for the tissue.
20. A medicinal composition comprising PBMCs obtained by the method as defined in any one of claims 1 to 16, wherein the medicinal composition is formulated for use in implantation or transplantation of an embryo in IVF suited during an in vitro ization (IVF) treatment.
21. The medicinal composition of claim 20, wherein the embryo is implanted or transplanted after cryopreservation.
22. The medicinal composition of claim 20 or 21, wherein the embryo transfer at least partially comprises contacting the embryo with the PBMCs.
23. The medicinal ition of any one of claims 20 to 22, wherein the ition is formulated for reducing a risk of embryo implantation failure or treating autoimmune infertility, unexplained infertility, recurrent or repeated implantation failure, unresponsive endometrium, thin endometrium, or another condition during fertility ent.
24. The medicinal composition of any one of claims 17 to 23, wherein the medicinal composition is formulated for stration to a non-human patient is of murine, or livestock animal origin.
25. A medicinal composition comprising PBMCs obtained by the method as defined in any one of claims 1 to 16 formulated for use in in vitro fertilization (IVF), wherein: (A) the ition also comprises human chorionic gonadotropin (hCG), due to culturing of cultured PBMCs in the e media with hCG, (B) the composition is for stration into the uterine cavity after a predetermined delay after oocyte retrieval in controlling ovary stimulation initiating ovulation, wherein the predetermined delay is equal to at least two months menstrual cycles or two cycles of ovulation, (C) the composition is for administration prior to embryo transfer in IVF, and wherein the use of the composition simultaneously complying with conditions (A)-(C) leads to a higher probability of successful embryo implantation in IVF, compared to IVF without use of the composition.
26. The medicinal composition of claim 25, wherein the predetermined delay is 3 to 12 months.
27. The medicinal composition of claim 25 or 26, wherein the volume of the composition introduced into the uterine cavity is in the range of 0.1 to 0.3 mL.
28. The medicinal ition of any one of claims 25 to 27, wherein the composition is for administration 20 to 72 hours prior to embryo transfer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ807980A NZ807980B2 (en) | 2012-11-21 | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629651P | 2011-11-23 | 2011-11-23 | |
| US13/655,257 US10271876B2 (en) | 2011-11-23 | 2012-10-18 | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells |
| NZ73514112 | 2012-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ792553A NZ792553A (en) | 2024-03-22 |
| NZ792553B2 true NZ792553B2 (en) | 2024-06-25 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Skidmore | Reproduction in dromedary camels: an update | |
| Baldassarre et al. | Advanced assisted reproduction technologies (ART) in goats | |
| Behr et al. | Factors relating to a successful cryopreserved blastocyst transfer program | |
| US5366888A (en) | Enhanced maintenance of pregnancy using leukaemia inhibitory factor in embryo culturing | |
| Paramio | In vivo and in vitro embryo production in goats | |
| Rasmussen et al. | Pregnancy rates of lactating cows after transfer of in vitro produced embryos using X-sorted sperm | |
| Lazzari et al. | Short-term and long-term effects of embryo culture in the surrogate sheep oviduct versus in vitro culture for different domestic species | |
| Kyono et al. | Birth and follow-up of babies born following ICSI using SrCl2 oocyte activation | |
| Dos Santos-Neto et al. | Embryo survival and birth rate after minimum volume vitrification or slow freezing of in vivo and in vitro produced ovine embryos | |
| WO2019061560A1 (en) | In vitro maturation culture medium of immature oocytes and use thereof | |
| Chang et al. | Two successful pregnancies obtained following oocyte vitrification and embryo re-vitrification | |
| García | Embryo manipulation techniques in the rabbit | |
| Virant-Klun et al. | Successful freezing and thawing of blastocysts cultured in sequential media using a modified method | |
| Looman et al. | In Vitro Embryo Production and Development in Livestock and Human: A One Health Model for Human Assisted Reproductive Technology | |
| EP3205716B1 (en) | Processing and use of fluids of the reproductive tract for improving the in vitro production of embryos of mammals | |
| NZ792553B2 (en) | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells | |
| NZ792553A (en) | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells | |
| KR102654800B1 (en) | Composition of in vitro fertilization and in vitro culture medium for aged oocyte containing lipoic acid and resveratrol | |
| EVANS et al. | Human in vitro fertilization | |
| NZ807980B2 (en) | Method of In Vitro Fertilization with Delay of Embryo Transfer and Use of Peripheral Blood Mononuclear Cells | |
| NZ807980A (en) | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells | |
| Menkir et al. | In-vitro embryo production and transfer technology in cattle: An updated review article | |
| El-Nahla et al. | Effect of season and maturation time on oocyte competence and in vitro maturation of dromedary camel oocyte | |
| De Geyter et al. | First delivery of healthy offspring after freezing and thawing of oocytes in Switzerland | |
| Ким et al. | EFFICACY OF USING CULTURE MEDIA IN ASSISTED REPRODUCTIVE TECHNOLOGY PROGRAMS |